In lung cancer, radiomics has been shown to predict pathological response, metastasis, and survival, and to correlate with histology, mutations [19,20,21,22,23,24,25], PD-L1 expression [13,26], and immunotherapy response [17,27,28]. This evidence concerns the gene CD274 and lung cancer.